PLRX / Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled

Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that its mid-stage study on lead pipeline candidate bexote more_horizontal

Pliant Therapeutics is a clinical-stage biotech. The company said it has enough cash to fund operations through the second half of 2026. more_horizontal

Pliant Therapeutics Inc. shares PLRX, -2.86% gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatme more_horizontal

Pliant Therapeutics is a biotech company focused on developing therapies for fibrotic diseases. The company's financials show an increase in R&D and a more_horizontal

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compar more_horizontal

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compar more_horizontal

Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market more_horizontal

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do more_horizontal